Dec 20, 2018
Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors
Online investor portal Proactive Investors highlighted Starpharma’s VivaGel® BV US license deal with ITF Pharma, worth $142 million plus escalating double digit royalties. The piece noted ITF Pharma’s strong pedigree in women’s health and their high-calibre team.
To read the article, click here.